Step Towards Type 1 Diabetes Vaccine Using Nanotherapy
Step Towards Type 1 Diabetes Vaccine Using Nanotherapy. Two years ago, the Immunology of Diabetes Research Group at the Germans Trias Research Institute (at Universitat Autònoma de Barcelona — Campus of International Excellence Sphere) reported a new experimental immunotherapy that prevented the onset of Type 1 Diabetes in mice predisposed to the disease. This work led to more studies with the support of the Spanish Government, Catalan Government and private patrons with a keen interest in it. Thanks to this, the article published in PLOS ONE describes a new step towards the creation of a vaccine, which in the medium-term could be capable of preventing and even curing the disease in humans.
Initially the researchers avoided the destruction of the insulin-producing pancreatic cells (beta cells) in the body by modifying the individual’s immune cells, known as dendritic cells. This important step requires the extraction of the subjects’ dendritic cells for their subsequent manipulation and re-injection. The process is complex and costly. In a new study with mice researchers have achieved the same effect with a much simpler process.
Nanoparticles called liposomes are created in the laboratory; when they are introduced into the body they arrest the destruction of the beta cells and avoid diabetes development.
This technique could be a much better candidate for a human vaccine. The invention is commercially protected and an international patent has been applied for.
Droplets of fat and water which can be produced on a large scale
Liposomes have been used in several medical treatments. They are not cells, but droplets with an external fat membrane, similar to cell membranes. They can be made using a very specialized process, but one that is easy and safe and also easy to scale up.
The key: beta cells in process of natural death
To complete this study Germans Trias researchers have worked together with a ICREA group from the Catalan Institute for Nanoscience and Nanotechnology (ICN2). The ICN2 is a Severo Ochoa Center of Research Excellence located on Universitat Autònoma de Barcelona (UAB) Campus, and its mission is to seek nanotechnology solutions to challenges in the fields of biology, energy or technology. The diameter of the liposomes created for this collaborative work is from half to one micron. They were specifically generated to imitate beta cells of the pancreas that are in the process of programmed cell death (apoptosis). As the researchers showed during the previous studies, this is the way to prevent the body from destroying the beta cells and to allow it to recuperate immunological tolerance. The Catalan researchers are the first group in the world to use liposomes that imitate naturally dying cells to fight against diabetes. The Universities of Barcelona and Lleida also contributed to this work.
After showing that liposomes prevent the onset of Type 1 Diabetes in mice, the next steps are to test it in human cells in vitro, to start clinical trials on human candidates for preventive vaccination and to cure the disease by combining the vaccine with regenerative therapies. The Germans Trias Institute plans to carry out these steps with patients at the hospital and to optimize the product by dosage and guideline studies. It is also planned to optimize the product for personalization. To achieve these objectives more competitive funding will be necessary from public agencies. The group is also studying collaborations and investment opportunities from the pharmaceutical industry. Private funding continues to be important and the Germans Trias Institute is studying the possibility of organizing a local campaign.
Growing incidence and complex consequences
Type 1 Diabetes is an illness where the body does not recognize the beta cells of the pancreas as its own and destroys them. The organ produces less and less insulin, the hormone that allows us to process the sugar we eat. Patients must inject themselves with insulin in the stomach or other parts of the body. This constant control is not always easy and having too much or too little insulin can have severe consequences. The most serious is that in the long term hyperglycemia provokes retinal damage that can lead to blindness, renal insufficiency, destruction of nerve fibers or what is called “Diabetic’s Foot” where ulcers form, leading eventually to the need to amputate.
The causes of the disease are unknown, although there are both genetic and environmental factors involved. About 0.3% of the population is affected and the incidence is increasing by 3-4% a year. It usually appears in children and young adults. This immunotherapy presents a possible solution for Type 1 Diabetes.
This research is quite encouraging, but it is still only in the mouse study development phase. Much promising research has dramatically different results once studied in humans. Tiime will tell, but we hope to hear more about this in the future.
Until we have a cure for type 1 diabetes, it is our opinion that mastering this disease in the healthiest way possible through lifestyle innovations as a priority over drug therapies is vital. It is important for optimal blood sugar control today, but it can help put your body in a position of strength for tomorrow – for that day when the cure for type 1 diabetes may be found.
Our recipe e-books, workshops and home study course will teach you how to transform your lifestyle in a practical, livable way for long term sustainability and better living. Our support services can make the difference between success and failure during your transformation. And our advanced resources will take you deeper into practical application and underlying research. Let us help you shorten the learning curve to successful lifestyle transformation by setting you on the path toward optimal blood sugar control and better living.
Journal Reference: Irma Pujol-Autonell, Arnau Serracant-Prat, Mary Cano-Sarabia, Rosa M. Ampudia, Silvia Rodriguez-Fernandez, Alex Sanchez, Cristina Izquierdo, Thomas Stratmann, Manuel Puig-Domingo, Daniel Maspoch, Joan Verdaguer, Marta Vives-Pi. Use of Autoantigen-Loaded Phosphatidylserine-Liposomes to Arrest Autoimmunity in Type 1 Diabetes. PLOS ONE, 2015; 10 (6): e0127057 DOI:10.1371/journal.pone.0127057